PROMISE
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
What will happen during the trial?
The goal of the PROMISE research study is to determine clinical/genomic alterations present in individuals with MGUS and SMM, who are diagnosed though screening of a high-risk population. We also seek to determine clinical/genomic/epigenetic and immune environmental predictors of progression to multiple myeloma in patients with MGUS and SMM.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Observational Trial
- Enrollment
- 30,000 patients (estimated)
- Sponsors
- Dana-Farber Cancer Institute
- Collaborators
- Stand Up To Cancer
- Tags
- High Risk, Observational, Participate From Home
- Trial Type
- Observational
- Last Update
- 1 month ago
- SparkCures ID
- 979
- NCT Identifier
- NCT03689595
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.